HER2-positive Recurrent or Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch HER2-positive Recurrent or Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer (NCT07545044) | Shanghai JMT-Bio Inc. | 2026-05-30 |
Track HER2-positive Recurrent or Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.